Tumor markers such as CEA and CA 19-9 were measured postoperatively; however, their inclusion in the primary analysis was avoided, as the timing of assessment, only 14 days after surgery, was considered too early to yield clinically meaningful insights. The gene discussed is CEACAM5; the disease is neoplasm.